Recombinant Human Interleukin-2

Phase 2Protein / enzyme

SSecond Xiangya Hospital of Central South University

Recombinant Human Interleukin-2 is one of 126 small molecule programs targeting Pemphigus Vulgaris. It is currently in Phase 2.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pemphigus VulgarisActive, not recruiting

AdenocarcinomaActive, not recruiting

Pleural EffusionActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

Pemphigus VulgarisPhase 2

Active, not recruiting

AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Pleural EffusionPreclinical

Active, not recruiting

Chronic Spontaneous UrticariaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

47 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

32 4

Taxol

Teva

Phase 3

13 5

Taxotere

AAvyxa

Phase 3

19 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

19 7

Beyfortus

BeiGene

Phase 3

5 8

Iressa

AstraZeneca

Phase 3

4 9

Cyramza

Eli Lilly

Phase 3

4 10

Ellence

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated·CCelularity Incorporated·Phase 1/2·NCT05207722·1 enrolled

HER2 Positive1 trial

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Unknown status·YYi Miao·Phase 1·NCT02662348·6 enrolled

Solid Cancers1 trial

ACTolog in Patients With Solid Cancers

Completed·IImmatics US, Inc.·Phase 1·NCT02876510·38 enrolled

Chronic Spontaneous Urticaria1 trial

Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 2/3·NCT04893980·56 enrolled

Pemphigus Vulgaris1 trial

Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 2·NCT04023149·180 enrolled

1 more indication

Pleural effusion1 trial

Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion

Unknown status·PPeking Union Medical College·N/A·NCT04131231·248 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Recombinant Human Interleukin-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human Interleukin-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human Interleukin-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: SSecond Xiangya Hospital of Central South University

Recombinant Human Interleukin-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adenocarcinoma1 trial

HER2 Positive1 trial

Solid Cancers1 trial

Chronic Spontaneous Urticaria1 trial

Pemphigus Vulgaris1 trial

Pleural effusion1 trial

References

Drug Info

Quick Facts

Related News